List of members
Dr. Alan Bell, MD, is a family physician and clinical researcher in Toronto, Canada. He is Assistant Professor in the Department of Family and Community Medicine, University of Toronto and on the active staff of the Humber River Hospital. He is a recipient of the College of Family Physicians of Canada Award of Excellence.
His activities include:
- Primary Panel and Past Chair – Canadian Cardiovascular Society Antiplatelet Guideline Committee.
- Primary Panel – Canadian Cardiovascular Society Atrial Fibrillation Guideline Committee
- Thrombosis Canada – Board of Directors
- Hypertension Canada – Board of Directors
- Canadian Stroke Network Professional Development Committee
Dr. Bell’s involvement in continuing medical education includes the development and presentation of many national projects. He has served as faculty and chair of countless committees and advisory boards dedicated to serving the common interests of the medical profession and the public. His research, commentaries and letters have been presented and published internationally.
Dr. Lynne Belle-Isle, PhD, is a National Programs Manager with the Canadian AIDS Society and a Research Affiliate at the Centre for Addictions Research of BC, University of Victoria. She is co-founder and Chair of the Canadian Drug Policy Coalition. She has a MSc in Epidemiology and a PhD in Social Dimensions of Health.
Lynne has been conducting community-based research on barriers and facilitators to access to medical cannabis in Canada for people living with a variety of conditions. Her research on “Barriers to access to medical cannabis for Canadians living with HIV/AIDS” was published in AIDS Care in April 2007 and was used in various court cases challenging the constitutionality of the Marihuana Medical Access Regulations. This work led to collaboration with Dr. Zach Walsh and others on the Cannabis Access for Medical Purposes (CAMPS) Study (2014) and the ongoing Cannabis Access Regulations (CANARY) Study with Dr. Lynda Balneaves, Ms Rielle Capler, and others. Lynne has also co-authored papers on cannabis dispensaries (Capler, et al., 2017), cannabis substitution for prescription drugs, alcohol, and other substances Lucas, et al., 2015), and cannabis and HIV/AIDS (Ware & Belle-Isle, 2010).
Lynne sat on Health Canada’s Stakeholder Advisory Committee on Medical Marihuana [sic] in 2004/2005. She has authored submissions to Health Canada on various amendments to the regulations, and co-authored submissions to the Task Force on Cannabis Regulation and Legalization from the Canadian Drug Policy Coalition, the Centre for Addictions Research of BC, and a joint submission from The Arthritis Society, Canadians for Safe Access to Medical Marijuana, and the Canadian AIDS Society.
Lynne has offered numerous community and academic workshops and webinars on the use of cannabis for medical purposes. She has brought together key stakeholders and facilitated collaboration on work related to medical cannabis, including serving on the planning committee for The Arthritis Society’s Medical Cannabis Research Roundtable in 2016. She authored the Canadian AIDS Society’s Position Statement on HIV and the Therapeutic Use of Cannabis. The Canadian AIDS Society was the first national non-governmental organization to adopt such a position in May 2004. On October 4th, 2017, the Canadian AIDS Society received the Lifetime Achievement Award from the Canadian Medical Cannabis Council in recognition of its leadership in advancing the cause of medical cannabis patients in Canada.
Dr. Paul Daeninck, MD, has worked as a medical oncologist and palliative medicine consultant with CancerCare Manitoba since 1998.
He is the Chair of the Symptom Management and Palliative Care Disease Site Group at CancerCare Manitoba, and an Assistant Professor at the Rady College of Medicine, University of Manitoba.
Dr. Daeninck serves with national organizations, including the Royal College of Physicians and Surgeons, Canadian Partnership Against Cancer, Canadian Consortium for the Investigation of Cannabinoids, and the DeSouza Institute.
He is active in medical student and resident education as well as involved in research of several aspects of palliative medicine, including the role of medical cannabis in cancer therapy.
Dr. Marilou Gagnon, PhD, is Associate Professor at the School of Nursing, Faculty of Health Sciences, University of Ottawa and Director of the Unit for Critical Research in Health. Her work is underpinned by critical and sociopolitical approaches. Her fields of study include questions related to the body and technology, power and discourse, and social justice.
As a member of the University Chair in Forensic Nursing, she is working on a number of projects on HIV criminalization, HIV-related stigma and discrimination in health care settings, and human rights. She served on the board of directors of the Canadian Association of Nurses in AIDS Care (CANAC) (2009–13) and was Expert Advisor Research, Policy and Advocacy for CANAC from 2013-16. She also served on the board of the Bureau Régional d’Action Sida (BRAS) in Gatineau (2012-14) and joined the Canadian HIV/AIDS Legal Network’s board of directors in 2013 for a first mandate and a second mandate in 2015. She currently serves as Vice-Chair of the Legal Network’s Board.
She is the Founder of the Coalition of Nurses and Nursing Students for Supervised Injection Services, creator of the Facebook campaign Harm Reduction = Nursing Care, and founder and editor of the blog Radical Nurse. She also co founded the Harm Reduction Nurses Association and is currently serving as President.
In November 2015, Gary Lacasse became the Executive Director of the Canadian AIDS Society with the goal of meeting the ever-changing needs of people living with HIV/AIDS. After serving as the Executive Director of Maison Plein Coeur, one of Quebec’s largest AIDS service organizations, he joined CAS at a pivotal moment: when we needed a new and engaging leadership to fulfill the needs of our community.
Before working in non-profits, Gary spent over two decades in the private sector and was Strategic Director in sales and marketing at the end of his career there. But after deciding to shift his professional priorities entirely, he redirected his focus to the not-for-profit sector. By guiding organizations with his financial and communications experience, Gary was able to lend his knowledge to a number of groups, including COCQ-sida, The Council for Quebec Gays & Lesbians, the Tremblant Chamber of Commerce, Fondation Tremblant.
Gary also served as a member on CAS’ board of directors, a role that would ultimately allow him to understand the internal workings of CAS. This insight needed to pivot our focus and once again engage Canadians in the conversation about HIV/AIDS.
With Gary comes transparency, humility and direct acknowledgement of our valued board members in all our direction and decision making process. “I want to talk about real things.” he says, adding “We have to own it and work it and keep people talking about it at a high level. How are we going to have zero infections without an open and dynamic discussion about it? Our foundation is there. It’s intact. Right now we are just building our walls back up.”
Dr. MacCallum completed her undergraduate degree in pharmacy and medicine at Memorial University of Newfoundland , where she was born and raised. She graduated from the University of British Columbia Internal Medicine Residency Program in 2013. Upon graduation, she practiced pain & addiction medicine at Vancouver General Hospital and Heartwood Addiction Program at BC Women’s Hospital. In addition she also practiced complex pain medicine at the CHANGEpain Clinic and BC Women’s Complex Chronic Disease Program.
Currently she is a clinical instructor in the UBC Department of Medicine at where she provides inpatient care on the Internal Medicine Ward at UBC Hospital, and Bone Marrow Transplant Ward at VGH. She is also guest lecturer and preceptor for UBC Faculty of Pharmaceutical Sciences Program.
She is the Medical director at Greenleaf Medical Clinic. Dr. MacCallum has a passion for cannabis education and curriculum. She has done a number of CME presentations and preceptorships for physicians, pharmacists, nurses and other allied health care professionals.
Her research interest include: cannabis to help taper prescription medications to reduce overall polypharmacy burden; cannabis in complex diseases; cannabis impairment and cannabis use in the workplace.
Enrico Mandarino has over 25 years of experience as a healthcare professional within the hospital, educational and pharmaceutical industries. His breadth of experience in healthcare includes progressive positions in diagnostic and clinical research, health policy, stakeholder relations, patient assistance, education and quality assurance.
Enrico holds an associates degree in Medical Laboratory Science and a postgraduate certificate as a Clinical Research Associate from the Michener Institute of Applied Health Sciences. He is also completing a Bachelor of Health Administration, from Ryerson University. As a Regulated Health Professional, he maintains an active practicing registration with the College of Medical Laboratory Technologists of Ontario. Enrico has contributed to numerous public policy and clinical research initiatives and co-authored several published clinical and public policy papers.
Enrico has served on several national health related boards and was recently appointed to the Canadian Institutes of Health Research (CIHR), Community Advisory Committee and the Scientific Review Committee. Enrico is passionate about engaging diverse stakeholders across all sectors in basic and clinical science research and integrated knowledge translation; to ensure strategic directions on emerging health issues are impact driven.
In 2012, Enrico was awarded the Queen Elizabeth Diamond Jubilee Medal, by the Governor General, for significant contributions to Canada.
Shari Margolese has been an active voice for people living with HIV since her own diagnosis in 1992. Shari began using cannabis to fight the side effects of HIV medication and progressing illness including advanced arthritis. Her advocacy for access to medical cannabis includes conference abstract presentations nationally and internationally spanning almost 20 years.
Additionally, Shari served on the Health Canada Advisory Committee for the Medical Marijuana Access Regulations. Most recently Shari contributed to the Task force on Marijuana report as a member of the community panel.
As a community research consultant and writer, Shari has many publications including Canadian Clinical Guidelines for HIV Pregnancy Planning. Currently, Shari chairs the CIHR Canadian HIV Trials Network Community Advisory Committee. Shari is a recipient of the Queen Elizabeth Golden Jubilee Medal for her service to community.
Dr Danial Schecter, MD, is the co-founder and medical director of the Canadian Cannabinoid Medical Clinic (CMClinic), one of the largest referral only clinics in Canada specializing in cannabinoid medicine.
He is a practicing family physician who has trained dozens of physicians in the field and has lectured at over a hundred events internationally.
Danial has established a unique skill set that includes both patient care and cannabinoid education. He spearheaded the creation of the Patient Handbook on Medical Cannabis used by many Canadian physicians as a patient education tool and has evaluated thousands of patients to decide if cannabinoid medicines are appropriate for them.
Dr. Zach Walsh, PhD, is a clinical psychologist and an Associate Professor of Psychology at the University of British Columbia, where he directs the Therapeutic Recreational and Problematic Substance Use lab.
He has published more than 50 research articles and chapters, and has presented and consulted to diverse governmental, professional, and public audiences on topics related to cannabis, mental health, and public health.
He is the lead investigator for several ongoing studies of the therapeutic use of cannabis including a clinical trial of cannabis for Post-traumatic Stress Disorder.
His work has been supported by the Canadian Institutes of Health Research, Social Sciences and Humanities Research Council of Canada, the American Psychological Association, and others.
Janet Yale currently serves as president and CEO of The Arthritis Society after years of providing results-oriented leadership in c-suite positions in the private, public and not-for-profit world. An accomplished senior executive with a long history in the telecommunications sector, Janet previously served as executive vice president at TELUS and president and CEO of the Canadian Cable Television Association. A lawyer and economist by training, Janet worked early in her career as a director general at the CRTC and as general counsel to the Consumers Association of Canada.
Janet’s true passion is in the not-for-profit sector where she has been recognized as a proven innovator and leader. She is chair of the Arthritis Alliance of Canada, Past-Chair of the Ontario Trillium Foundation and serves on the boards of Samara and the Ottawa Art Gallery.
Janet is a recipient of the Queen Elizabeth II Diamond Jubilee Medal, a winner of the Woman Leader of the Year by the Federated Press and Businesswoman of the Year by the Women’s Business Network.
Jonathan Zaid is Founder and Executive Director of Canadians for Fair Access to Medical Marijuana (CFAMM) and a part-time Knowledge Integration student at the University of Waterloo.
In 2007, he was diagnosed with New Daily Persistent Headache, a rare neurological condition that causes constant head pain and insomnia. After trying all available interventions to no avail, Jonathan finally gained some relief from medical cannabis. Zaid was among the first to successfully advocate for medical cannabis to be covered under a benefits plan (University of Waterloo FEDS’ plan). In an effort to further improve the rights of Canadian medical cannabis patients, Jonathan founded CFAMM, a national non-profit organization. Under Jonathan’s leadership, CFAMM has grown to be one of the most respected and effective medical cannabis patient groups. Zaid currently sits as Chair of the Canadian Medical Cannabis Council’s Patient Advisory Committee and is an editorial board member for “Using Medical Cannabis”, a quarterly medical cannabis publication.
Zaid is recognized as a leading industry expert on the cost-coverage of medical cannabis and other patient-related issues. He is widely seen advocating for patients’ rights at various conferences and panels and is frequently featured in television, radio, newspaper, and blog interviews.
Dr. Ware is Associate Professor in Family Medicine and Anesthesia at McGill University. He is Director of Clinical Research of the Alan Edwards Pain Management Unit at the McGill University Health Centre and Executive Director of the Canadian Consortium for the Investigation of Cannabinoids (CCIC).
Dr. Cecilia Costiniuk received her medical degree from McMaster University followed by residency training in internal medicine and infectious diseases from the University of Ottawa. This was followed by a Master’s in Microbiology and Immunology from the University of Ottawa and then an HIV/Tuberculosis research followship at the KwaZulu-Natal Research Institute for Tuberculosis and HIV in Durban, South Africa.
Following her return to Canada in 2014, Dr Costiniuk joined McGill University’s Department of Medicine, Division of Infectious Diseases/Chronic Viral Illness Service as assistant professor of medicine. A clinician investigator, she leads a research program funded by the CIHR and Fonds de recherche du Québec—Santé (FRQ-S) focused on chronic lung disease, pulmonary immunity and inflammation in the context of HIV infection. She also holds a Chercheur-boursier-clinicien Junior 1 salary award from the FRQ-S.
Dr Costiniuk is interested in exploring the therapeutic potential of cannabinoids for various conditions affecting people living with HIV in the context of well-designed clinical studies. She is especially interested in examining the role of cannabinoids as anti-inflammatory agents in the context of chronic HIV. She is the lead investigator on an upcoming pilot study supported by the CIHR-CTN (PT028) which will investigate the safety, tolerability and effects on inflammation of cannabinoids in the context of HIV infection.
For more information on the ongoing Cannabis Guidelines Project, please go to our Research page.